Key facts
- Marea’s last known valuation is $272.0M.
- It has raised $190.0M; the latest was Early Stage VC ($160.0M) in Jun 2024.
- Notable investors include Alpha Wave Global, Forbion, Perceptive Advisors, Omega Funds, Surveyor Capital — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for Marea
- ·The full record, as it builds
Funding rounds
No funding rounds for Marea are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Marea
Operator of a biotechnology company intended for the treatment of cardiometabolic diseases. The company specializes in the development of novel therapies for patients at risk for heart attacks, enabling patients to reduce remnant cholesterol and metabolic dysfunction and enhance the overall efficiency of the treatment process.
- Sector
- Healthcare
- HQ
- San Francisco, CA, United States
- Founded
- 2022
- Employees
- 32
- Website
- mareatx.com/
- Ownership
- Privately Held (backing)
Marea doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Marea shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Marea in its N-PORT filings yet. We sweep new filings monthly.